Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYongping SongZZZunmin ZhuJWJianyu Weng

Discussion

Loading...

Member takes

Overview

Interim results demonstrate LeukoPrint improves CNA detection in Acute Myeloid Leukemia, suggesting significant prognostic value.

Key Points

  • LeukoPrint shows improved detection of copy number aberrations in acute myeloid leukemia.
  • Using LeukoPrint, 42.4% of patients exhibited CNAs versus 27.3% with conventional karyotyping.
  • Prospective multicenter clinical trial monitoring genotypes and treatment responses across multiple hospitals.
  • Highlights the potential of LeukoPrint to enhance existing cytogenetic methods in evaluating clinical outcomes.

Cite This Study

Song et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e032https://doi.org/10.1182/blood-2025-5245
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.2025 · 1 citations
  2. 2Rapid and Reproducible Karyotyping with Long Read Sequencing in AML Patients2026
  3. 3Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report2025
  4. 4Results of molecular-cytogenetic studies in cases of suspected chronic myeloid leukemia2025
  5. 5Development and clinical evaluation of a cost-effective method with capillary electrophoresis sequencer-based fragment analysis assay panel for genetic classification and risk stratification in de novo AML2025